Healthcare Global Enterprises Ltd logo

Healthcare Global Enterprises Ltd

HCG NSE

Key Fundamentals

MicrocapHospitalsHealthcare Services
Market Cap
₹10,606 Cr
Volatility
Moderate
P/E Ratio
466.44
EBITDA
₹414 Cr
Return on Equity
4.93%
Debt to Equity
1.3
Book Value
₹89.21
EPS
₹3.57
52W High
₹799.71
52W Low
₹513.3

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Healthcare Global Enterprises Ltd insights

50 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

5
  • Stock is trading at 8.00 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 4.25% over last 3 years.
  • Promoter holding has decreased over last 3 years: -7.14%

Growth Rate

Revenue Growth
12.43% ↗
Net Income Growth
-85.33% ↘
Cash Flow Change
11.43% ↗
ROE
3.14% ↘
ROCE
-5.78% ↘
EBITDA Margin (Avg.)
-13.64% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 43d ago
AI opinion · based on fundamentals
Risk high

Healthcare Global Enterprises Ltd operates in India's oncology-focused hospital segment with a market cap of Rs 9,734.5 crore and trades at a PE of 430.2x. The company has delivered consistent 15-16% revenue CAGR over 3-10 year periods but profitability remains under pressure with TTM profit declining 36% and ROE averaging just 4% over 3-5 years.

Bull Case 7
  • Consistent revenue growth with compounded sales CAGR of 15% over 3 years and 20% over 5 years, indicating strong demand for oncology services
  • TTM revenue growth remains healthy at 15%, showing continued momentum in top-line expansion
  • Long-term profit CAGR of 39% over 10 years demonstrates the company's ability to scale earnings over extended periods
  • Stock CAGR of 24% over 5 years and 26% over 3 years reflects sustained market confidence in the business model
  • 5-year compounded profit growth of 18% shows the company has historically been able to convert revenue growth into earnings
  • Operates in India's underpenetrated oncology care segment where cancer incidence is rising, supporting the 16% 10-year sales CAGR
  • Market cap of Rs 9,734.5 crore provides scale and institutional visibility in the specialty healthcare space
Bear Case 8
  • PE ratio of 430.2x is extremely elevated, implying the stock prices in massive future growth that may not materialize
  • TTM compounded profit has declined 36%, signaling a sharp deterioration in near-term earnings
  • 3-year ROE of just 4% and last year ROE of 3% indicate poor capital efficiency for a company trading at 7.38x book value
  • Price-to-book ratio of 7.38x is very high relative to the low single-digit ROE, suggesting a valuation disconnect
  • Promoter holding has decreased by 7.16% over last 3 years, raising questions about insider confidence
  • Zero dividend yield despite reporting profits indicates no capital return to shareholders
  • Low interest coverage ratio suggests the debt burden is straining operating profits
  • 10-year ROE averages negative 1%, showing the company has struggled to generate adequate shareholder returns over a full cycle

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 43d ago
Neutral 4
  • Stake sale in BACC Healthcare Jun 29

    HCG sold 99.999% stake in BACC Health Care Private Limited for ₹37.64 crore, with initial consideration of ₹28.23 crore received on June 29, 2026.

  • Promoter encumbrance release on 7.16Cr shares Jun 15

    Hector Asia Holdings II Pte. Ltd. released a non-disposal undertaking on 7,16,77,991 shares, reducing promoter encumbrance overhang.

  • No new encumbrance in FY26 Jun 16

    Promoter Dr. B.S. Ajaikumar declared no new encumbrance on shares in FY26; total encumbered shares stand at 49,59,539 (3.32% of paid-up capital).

  • ESOP scheme and director reappointment Jun 8

    HCG initiated postal ballot for five special resolutions including a new ESOP scheme and reappointment of an independent director, with e-voting open June 09 to July 08, 2026.

TL;DR: Recent news flow for HCG is largely corporate housekeeping with no material headwinds or strong positives. The BACC stake sale brings in ₹37.64 crore and the significant promoter encumbrance release is mildly reassuring on governance. With no operational or earnings updates in this batch, the near-term outlook depends on upcoming quarterly results and broader oncology sector demand trends.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
461
487
470
495
526
554
559
585
613
647
633
652
695
Expenses
386
402
391
403
435
451
470
480
505
524
524
527
573
Operating Profit
74
85
79
92
91
102
88
106
108
123
110
125
122
OPM %
16%
17%
17%
19%
17%
18%
16%
18%
18%
19%
17%
19%
18%
Other Income
3
3
6
9
9
11
6
10
8
3
-10
-18
13
Interest
26
27
29
27
34
36
41
44
45
44
45
43
40
Depreciation
41
43
44
46
47
50
57
58
58
63
61
63
70
PBT
11
18
11
28
19
28
-3
14
12
20
-6
1
25
Tax %
65%
40%
69%
17%
28%
25%
-335%
50%
50%
-4%
30%
-223%
34%
Net Profit
4
11
3
23
14
21
8
7
6
21
-8
4
16
EPS in Rs
0.52
0.92
0.39
1.44
0.82
1.22
0.47
0.5
0.32
1.09
-0.63
0.15
0.92
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
519
584
700
829
976
1,092
1,009
1,395
1,691
1,908
2,218
2,545
2,627
Expenses
443
499
595
713
864
936
887
1,161
1,394
1,581
1,835
2,080
2,147
Operating Profit
76
85
105
116
112
157
122
234
297
327
384
466
480
OPM %
15%
15%
15%
14%
11%
14%
12%
17%
18%
17%
17%
18%
18%
Other Income
0
-2
10
25
10
10
-72
110
15
24
39
-18
-13
Interest
34
38
23
42
70
138
119
98
104
109
155
177
171
Depreciation
39
44
57
71
85
148
159
158
163
174
211
244
257
PBT
3
0
35
27
-33
-119
-229
88
45
68
57
27
40
Tax %
-56%
-730%
34%
38%
-7%
5%
-3%
56%
61%
39%
14%
15%
—
Net Profit
5
2
23
17
-31
-125
-221
39
18
41
49
23
33
EPS in Rs
0.11
-0.16
2.44
2.23
-2.66
-11.36
-14.58
3.65
1.99
3.27
3.01
0.92
1.53
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
70
85
86
87
88
89
125
139
139
139
139
149
Reserves
210
341
347
428
389
293
572
731
721
686
783
1,183
Borrowings
349
324
420
464
658
1,347
977
915
901
1,274
1,837
1,735
Other Liabilities
147
294
372
461
515
518
357
433
549
601
780
855
Total Liabilities
776
1,043
1,225
1,440
1,650
2,246
2,031
2,218
2,311
2,701
3,540
3,923
Fixed Assets
528
583
685
828
970
1,646
1,382
1,547
1,553
1,758
2,442
2,462
CWIP
42
121
148
174
153
46
30
22
18
83
25
19
Investments
0
64
11
53
49
34
26
9
10
10
11
14
Other Assets
205
275
381
385
478
520
593
641
730
850
1,062
1,428
Total Assets
776
1,043
1,225
1,440
1,650
2,246
2,031
2,218
2,311
2,701
3,540
3,923
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
60
73
91
98
98
130
121
220
252
285
317
347
Investing
-79
-204
-210
-283
-238
-101
-171
125
-133
-226
-488
-177
Financing
22
216
89
161
84
-58
112
-155
-140
-64
-42
241
Net Cash Flow
2
85
-29
-24
-56
-30
62
190
-22
-5
-213
410
Free Cash Flow
-20
-137
-101
-158
-90
23
85
150
126
101
110
59
CFO/OP
87
99
93
88
121
100
68
104
92
101
91
81
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
45
43
54
57
59
62
67
57
65
56
66
60
Inventory Days
36
32
40
46
45
35
32
31
33
33
33
32
Days Payable
208
264
272
274
303
234
221
199
214
216
210
185
Cash Conversion Cycle
-127
-188
-178
-171
-200
-136
-121
-112
-116
-127
-111
-93
Working Capital Days
-65
-96
-112
-74
-110
-102
-26
-43
-40
-70
-91
-61
ROCE %
7%
6%
7%
6%
3%
1%
-1%
5%
8%
9%
9%
8%

Shareholding Pattern

As of Jun 2026
Promoters 64.21%
DIIs 19.20%
Public 10.83%
Others 3.02%
FIIs 2.74%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
70.71%
68.41%
68.40%
71.44%
71.43%
71.42%
71.39%
71.38%
71.37%
71.35%
71.30%
71.29%
71.28%
71.25%
71.23%
71.23%
71.22%
62.46%
63.78%
63.77%
64.21%
64.21%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
6.28%
0.00%
6.74%
3.95%
4.29%
2.77%
2.45%
2.16%
3.59%
3.22%
2.75%
2.74%
DIIs
7.82%
7.86%
6.27%
5.52%
4.90%
3.56%
4.03%
4.40%
5.54%
6.58%
7.94%
6.66%
8.52%
10.89%
11.64%
12.94%
12.47%
13.22%
18.36%
18.30%
18.91%
19.20%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
7.05%
9.46%
10.83%
10.07%
10.84%
11.58%
11.21%
11.60%
11.44%
10.43%
9.96%
9.68%
9.39%
9.41%
9.33%
9.60%
10.43%
10.50%
10.41%
11.20%
10.79%
10.83%
Others
14.42%
14.26%
14.50%
12.97%
12.83%
13.44%
13.38%
12.61%
11.65%
11.63%
4.52%
12.37%
4.07%
4.49%
3.50%
3.46%
3.43%
11.66%
3.86%
3.51%
3.34%
3.02%
No. of Shareholders
13,891
15,065
20,573
22,362
23,663
23,018
24,672
28,707
28,858
25,931
27,327
27,289
27,195
26,529
29,670
32,820
45,394
47,028
46,970
45,366
47,576
48,905

Documents

1
Concall - Aug 2018 Aug 2018
2
Concall - Nov 2018 Nov 2018
3
Concall - Feb 2019 Feb 2019
4
Concall - May 2019 May 2019
5
Concall - Jan 2020 Jan 2020

Frequently Asked Questions about Healthcare Global Enterprises Ltd

What does Healthcare Global Enterprises Ltd do?
Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]
Where is Healthcare Global Enterprises Ltd (HCG) listed?
Healthcare Global Enterprises Ltd is listed on the Indian stock exchanges. It is listed on NSE: HCG and BSE: 539787. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Healthcare Global Enterprises Ltd belong to?
Healthcare Global Enterprises Ltd operates in the Healthcare Services sector within the Hospitals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has a market capitalisation of approximately ₹10606.43 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Healthcare Global Enterprises Ltd?
The Price-to-Earnings (PE) ratio of Healthcare Global Enterprises Ltd is 466.44. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Healthcare Global Enterprises Ltd?
Over the past 52 weeks, Healthcare Global Enterprises Ltd has traded between a low of ₹513.3 and a high of ₹799.71. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has a Return on Equity (ROE) of 4.93%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Healthcare Global Enterprises Ltd on Tapetide?
On Tapetide, you can view Healthcare Global Enterprises Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]

Website hcgoncology.com
CEO Manisha Kumar
Employees 6,736
Listed 2016-03-30
Face Value ₹ 10
Issued Size 14,10,07,637

Explore More

More in Healthcare Services → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List